KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 7,370,000 shares, an increase of 7.3% from the October 31st total of 6,870,000 shares. Based on an average trading volume of 415,400 shares, the days-to-cover ratio is presently 17.7 days.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at $2,468,697.48. This represents a 5.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the sale, the insider now owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 32,016 shares of company stock valued at $319,344. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in KALV. Price T Rowe Associates Inc. MD boosted its holdings in KalVista Pharmaceuticals by 4.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after purchasing an additional 944 shares during the last quarter. HighVista Strategies LLC grew its position in shares of KalVista Pharmaceuticals by 4.5% during the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after buying an additional 1,432 shares in the last quarter. ClariVest Asset Management LLC increased its stake in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after buying an additional 1,535 shares during the last quarter. Nicholas Investment Partners LP raised its holdings in KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock valued at $2,172,000 after acquiring an additional 1,714 shares in the last quarter. Finally, nVerses Capital LLC bought a new position in KalVista Pharmaceuticals during the 2nd quarter valued at $25,000.

KalVista Pharmaceuticals Trading Down 5.3 %

KALV stock opened at $9.73 on Wednesday. KalVista Pharmaceuticals has a 1 year low of $7.39 and a 1 year high of $16.88. The stock has a 50-day simple moving average of $10.96 and a 200-day simple moving average of $11.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. On average, research analysts expect that KalVista Pharmaceuticals will post -2.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KALV has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).